---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344594"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-08-11T20:05:48+00:00"
generated_at: "2026-08-11T20:07:11.311379+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised

## Summary
- Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.
- Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; topline interim data expected 1H 2027.
- TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients as of Aug 2026 cutoff.
- Completed $230M follow-on offering; cash and equivalents $455.4M as of June 30, 2026, runway into 2H 2028.
- Expanded Catalent partnership for commercial manufacturing; appointed Mike Johannesen as Chief Legal Officer in June 2026.

## SEC filing metadata
- accession: 0001193125-26-344594
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-08-11T20:05:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/0001193125-26-344594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344594
- JSON: https://secwatch.observer/filing/0001193125-26-344594.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.